病例对照研究设计中的偏倚问题-案例解析

2019-01-29 MedSci MedSci原创

案例:阳光暴露与多发性硬化发生风险的相关性 此项研究是基于特定人群的病例对照研究,受试者纳入标准为:来自澳大利亚塔斯马尼亚岛,年龄小于60岁,其祖父母或外祖父母中至少有一位出生于塔斯马尼亚岛。病例组多发性硬化患者均是在当地多发性硬化学会发布招募信息后自愿参加的,或是受医疗专业人士邀请参加,总计136例,这些患者都经临床和磁共振成像检查确诊为多发性硬化。研究人员为每例患者匹配2例未患多发性

案例:阳光暴露与多发性硬化发生风险的相关性 此项研究是基于特定人群的病例对照研究,受试者纳入标准为:来自澳大利亚塔斯马尼亚岛,年龄小于60岁,其祖父母或外祖父母中至少有一位出生于塔斯马尼亚岛。病例组多发性硬化患者均是在当地多发性硬化学会发布招募信息后自愿参加的,或是受医疗专业人士邀请参加,总计136例,这些患者都经临床和磁共振成像检查确诊为多发性硬化。研究人员为每例患者匹配2例未患多发性硬化者作为对照,从该人群中,随机选择性别和年龄相同的2人分配至对照组,符合条件者总计359例,回应率为76%。向受试者发放经验证的调查问卷,记录受试者16岁以前、正常情况下周末和假期暴露于阳光下的时间,将肌动蛋白损伤作为终身累积阳光暴露结果的标志,并对皮肤光化性损伤严重程度进行分级:1级(无损伤)~6级(严重恶化)。 研究结果显示,6~15岁期间,长时间暴露于阳光下(夏天周末或假期平均每天2~3 h或更长)与多发性硬化发生风险下降相关,校正比值比(OR)为0.31,95%可信区间(CI)为0.16~0.59。光化性损伤严重(4~6级损伤)是多发性硬化发生风险下降的独立相关因素(OR 0.32,95% C

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775443, encodeId=e9451e75443bb, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Oct 05 06:49:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672912, encodeId=839c16e291240, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sat Sep 21 17:49:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984134, encodeId=8412198413482, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Nov 10 05:49:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756164, encodeId=d6b21e561644d, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Fri Jan 10 10:49:00 CST 2020, time=2020-01-10, status=1, ipAttribution=)]
    2019-10-05 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775443, encodeId=e9451e75443bb, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Oct 05 06:49:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672912, encodeId=839c16e291240, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sat Sep 21 17:49:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984134, encodeId=8412198413482, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Nov 10 05:49:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756164, encodeId=d6b21e561644d, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Fri Jan 10 10:49:00 CST 2020, time=2020-01-10, status=1, ipAttribution=)]
    2019-09-21 hongbochen
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775443, encodeId=e9451e75443bb, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Oct 05 06:49:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672912, encodeId=839c16e291240, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sat Sep 21 17:49:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984134, encodeId=8412198413482, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Nov 10 05:49:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756164, encodeId=d6b21e561644d, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Fri Jan 10 10:49:00 CST 2020, time=2020-01-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1775443, encodeId=e9451e75443bb, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Oct 05 06:49:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672912, encodeId=839c16e291240, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sat Sep 21 17:49:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984134, encodeId=8412198413482, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Nov 10 05:49:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756164, encodeId=d6b21e561644d, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Fri Jan 10 10:49:00 CST 2020, time=2020-01-10, status=1, ipAttribution=)]
    2020-01-10 xugc

相关资讯

JAMA Oncol: 勿将癌症幸存者排除在临床试验外

相当高比例的美国癌症患者为既往癌症的幸存者,由于临床试验和观察性研究一般会将此类患者排除在外,因此这些患者的结局知之甚少。

Rheumatology:类风湿性关节炎患者治疗的真实有效性:随机对照vs观察性研究

2018年2月,发表于《Rheumatology (Oxford)》上的一项研究,考察了在随机对照试验(RCTs)和观察性研究中接受治疗的类风湿关节炎(RA)患者,药物在改善治疗效果的特征上是否具有差异。

Thorax:肥胖会增加哮喘的风险?

背景:有观察研究称肥胖会增加患哮喘的风险。然而,目前不清楚是否是由于肥胖者的喘息引起的哮喘风险增高。研究者以观察性和基因测试两种方法,研究高BMI是否与喘息和哮喘的高风险有相关性,以及高BMI和哮喘的相关性是否可以由喘息解释。方法:从哥本哈根总人口研究中获得85437例年龄在20-100岁之间的个人基因谱,包括FTO (rs9939609), MC4R (rs17782313), TMEM18 (

观察性研究文献评价标准

复旦大学附属华山医院血液科 复旦大学临床流行病学/循证医学中心 王星 王小钦  临床研究根据有无设计的干预措施,分为观察性研究和试验性研究,试验性研究主要类型包括随机对照研究(RCT)和非随机对照研究,观察性研究中最常用的是病例对照研究和队列研究。在阅读文献或荟萃分析时均须对文献质量进行客观评价,本文对观察性研究文献评价标准进行介绍。   目前,有许多针对非随机对照研究和观察性研究的评价工具(